Coagulopathy, following medical therapy, for carcinoma of the prostate.
Cancer of the prostate can be associated with coagulopathy characterized as primary fibrinolysis or diffuse intravascular coagulopathy (DIC) with secondary fibrinolysis. These complications are usually associated with surgical manipulation of the prostate or with advanced metastatic disease. This report describes a patient with DIC and fibrinolysis following medical management of advanced prostate cancer with gonadotropin-releasing hormone leuprolide, while receiving the androgen receptor blocking agent flutamide. This report suggests that release of procoagulant material from prostatic carcinoma may be so rapid following hormonal management that consumptive coagulopathy with fibrinolysis can follow. Shortened Abstract: Medical management with gonadotropin releasing hormone allowed the expression of consumptive coagulopathy in patients with metastatic prostate cancer.
Bern
Murray M
MM
The Cancer Center of Boston, Boston, MA 02120, USA. mbern@cancercenterofboston.com
D000368:Aged; D001778:Blood Coagulation Disorders / Q000209:etiology; D004211:Disseminated Intravascular Coagulation / Q000209:etiology*; D004359:Drug Therapy, Combination; D005342:Fibrinolysis; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D011471:Prostatic Neoplasms / Q000150:complications* / Q000628:therapy
D005485:Flutamide; D016729:Leuprolide